The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Ian M. Thompson

University of Texas Health Science Center at San Antonio

San Antonio

TX 78229



Name/email consistency: high



  • University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. 2001 - 2013
  • Departments of Surgery and Pathology and Cellular and Structural Biology, University of Texas HSC at San Antonio, The San Antonio Center for Biomarkers of Risk of Prostate Cancer (SABOR), San Antonio Cancer Institute, USA. 2004


  1. Long-term survival of participants in the prostate cancer prevention trial. Thompson, I.M., Goodman, P.J., Tangen, C.M., Parnes, H.L., Minasian, L.M., Godley, P.A., Lucia, M.S., Ford, L.G. N. Engl. J. Med. (2013) [Pubmed]
  2. Chemoprevention of prostate cancer. Thompson, I.M., Tangen, C.M., Goodman, P.J., Lucia, M.S., Klein, E.A. J. Urol. (2009) [Pubmed]
  3. Does the level of prostate cancer risk affect cancer prevention with finasteride? Thompson, I.M., Tangen, C.M., Parnes, H.L., Lippman, S.M., Coltman, C.A. Urology (2008) [Pubmed]
  4. The Prostate Cancer Prevention Trial and the future of chemoprevention. Thompson, I.M., Tangen, C.M., Lucia, M.S. BJU Int. (2008) [Pubmed]
  5. The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. Thompson, I.M., Tangen, C.M., Ankerst, D.P., Chi, C., Lucia, M.S., Goodman, P., Parnes, H., Coltman, C.A. J. Urol. (2008) [Pubmed]
  6. Prostate-specific antigen in the early detection of prostate cancer. Thompson, I.M., Ankerst, D.P. CMAJ (2007) [Pubmed]
  7. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. Thompson, I.M., Pauler Ankerst, D., Chi, C., Goodman, P.J., Tangen, C.M., Lippman, S.M., Lucia, M.S., Parnes, H.L., Coltman, C.A. J. Clin. Oncol. (2007) [Pubmed]
  8. Finasteride decreases the risk of prostatic intraepithelial neoplasia. Thompson, I.M., Lucia, M.S., Redman, M.W., Darke, A., La Rosa, F.G., Parnes, H.L., Lippman, S.M., Coltman, C.A. J. Urol. (2007) [Pubmed]
  9. Chemoprevention of prostate cancer: agents and study designs. Thompson, I.M. J. Urol. (2007) [Pubmed]
  10. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. Thompson, I.M., Tangen, C.M., Goodman, P.J., Lucia, M.S., Parnes, H.L., Lippman, S.M., Coltman, C.A. J. Urol. (2007) [Pubmed]
  11. Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: "what has been will be again, what has been done will be done again; there is nothing new under the sun." ECCLESIASTES 1:9. Thompson, I.M., Lucia, M.S., Tangen, C.M. Int. J. Epidemiol (2007) [Pubmed]
  12. Chemoprevention of prostate cancer: lessons learned. Thompson, I.M. BJU Int. (2007) [Pubmed]
  13. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. Thompson, I.M., Ankerst, D.P., Chi, C., Goodman, P.J., Tangen, C.M., Lucia, M.S., Feng, Z., Parnes, H.L., Coltman, C.A. J. Natl. Cancer Inst. (2006) [Pubmed]
  14. Does prostate volume affect accurate grading of prostate biopsies?. Thompson, I.M., Tangen, C.M. Nature Clinical Practice. Urology (2006) [Pubmed]
  15. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. Thompson, I.M., Chi, C., Ankerst, D.P., Goodman, P.J., Tangen, C.M., Lippman, S.M., Lucia, M.S., Parnes, H.L., Coltman, C.A. J. Natl. Cancer Inst. (2006) [Pubmed]
  16. PSA: a biomarker for disease. A biomarker for clinical trials. How useful is it?. Thompson, I.M. J. Nutr. (2006) [Pubmed]
  17. Defining high risk prostate cancer--where do we set the bar? A translational science approach to risk stratification. Thompson, I.M. J. Urol. (2006) [Pubmed]
  18. Recommendations for defining and treating high risk localized prostate cancer. Thompson, I.M., Carroll, P.R., Carducci, M.A. J. Urol. (2006) [Pubmed]
  19. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. Thompson, I.M., Tangen, C.M., Paradelo, J., Lucia, M.S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., Canby-Hagino, E., Crawford, E.D. JAMA (2006) [Pubmed]
  20. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. Thompson, I.M., Ankerst, D.P., Chi, C., Lucia, M.S., Goodman, P.J., Crowley, J.J., Parnes, H.L., Coltman, C.A. JAMA (2005) [Pubmed]
  21. Screening for prostate cancer: opportunities and challenges. Thompson, I.M., Bermejo, C., Hernandez, J., Basler, J.A., Canby-Hagino, E. Surg. Oncol. Clin. N. Am. (2005) [Pubmed]
  22. Phase III prostate cancer prevention trials: are the costs justified?. Thompson, I.M., Tangen, C.M., Klein, E.A., Lippman, S.M. J. Clin. Oncol. (2005) [Pubmed]
  23. Erectile dysfunction and subsequent cardiovascular disease. Thompson, I.M., Tangen, C.M., Goodman, P.J., Probstfield, J.L., Moinpour, C.M., Coltman, C.A. JAMA (2005) [Pubmed]
  24. First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement. Thompson, I.M., Albanes, D., Basler, J.W., Crawford, E.D., Denis, L.J., Djavan, B., Fleshner, N., Johnson-Pais, T.L., Klein, E.A., Kristal, A.R., Lucia, M.S., Parnes, H.L., Piazza, G.A., Platz, E.A., Pollock, B.H., Price, D.K., Reichardt, J.K., Tangen, C.M., Tolcher, A.W., McMann, M.C. J. Urol. (2004) [Pubmed]
  25. Relationship of body mass index and prostate specific antigen in a population-based study. Thompson, I.M., Leach, R., Troyer, D., Pollock, B., Naylor, S., Higgins, B. Urol. Oncol. (2004) [Pubmed]
  26. Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer. Thompson, I.M., Basler, J.A., Leach, R., Troyer, D., Klein, E., Brawley, O. Urol. Oncol. (2003) [Pubmed]
  27. The Prostate Cancer Prevention Trial: design, status, and promise. Thompson, I.M., Tangen, C., Goodman, P. World. J. Urol (2003) [Pubmed]
  28. Prevention of prostate cancer with finasteride: US/European perspective. Thompson, I.M., Klein, E.A., Lippman, S.M., Coltman, C.A., Djavan, B. Eur. Urol. (2003) [Pubmed]
  29. Prostate cancer prevention: what do we know now and when will we know more?. Thompson, I.M., Basler, J., Hensley, D., von Merveldt, D., Jenkins, C.A., Higgins, B., Leach, R., Troyer, D., Pollock, B. Clin. Prostate. Cancer (2003) [Pubmed]
  30. Association of African-American ethnic background with survival in men with metastatic prostate cancer. Thompson, I., Tangen, C., Tolcher, A., Crawford, E., Eisenberger, M., Moinpour, C. J. Natl. Cancer Inst. (2001) [Pubmed]
  31. The Prostate Cancer Prevention Trial: Current status and lessons learned. Thompson, I.M., Kouril, M., Klein, E.A., Coltman, C.A., Ryan, A., Goodman, P. Urology (2001) [Pubmed]
  32. Latent carcinoma of the prostate. Thompson, I.M. Eur. Urol. (2001) [Pubmed]
  33. Pharmacologic agents in complementary medicine in prostatic disease. Thompson, I.M. Drugs. Today (2001) [Pubmed]
WikiGenes - Universities